Skip to Content
Merck
  • Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium.

Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium.

Japanese journal of pharmacology (1995-06-01)
Y Ishii, K Muraki, A Kurihara, Y Imaizumi, M Watanabe
ABSTRACT

Electrophysiological effects of sematilide, a novel class III antiarrhythmic agent, were examined and compared with those of (+/-)sotalol in guinea pig left atrium by a conventional microelectrode technique. Application of 0.1-1000 microM sematilide or 1-1000 microM (+/-)sotalol concentration-dependently prolonged the duration of action potentials (APD) that were elicited by electrical stimulation at 1 Hz. Other parameters of action potentials such as the maximum upstroke velocity of phase 0 depolarization, action potential amplitude and resting membrane potential were not affected significantly by these drugs in the concentration ranges employed. The prolongation of APD by sematilide or (+/-)sotalol was accompanied by a corresponding increase in the effective refractory period (ERP). Approximately a 30% increase in ERP was obtained by the treatment with 5 microM sematilide or 100 microM (+/-)sotalol, suggesting that sematilide as a class III antiarrhythmic agent is approximately 20 times more potent than (+/-)sotalol on a molecular basis. When the stimulation rate was increased stepwise from 0.2 to 2 Hz, the relative increase in APD at 90% repolarization by the treatment with sematilide and (+/-)sotalol was slightly larger at 2 Hz than at 0.2 Hz, indicating that "reverse rate-dependence" was not observed under these conditions. These results may suggest a possibility that sematilide effectively blocks atrial arrhythmia.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sematilide monohydrochloride monohydrate, ≥98% (HPLC), powder